Related Articles
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement‑positive non‑small cell lung cancer: A case report
Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report
Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment
Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients